Microbot Medical Announces Multiple Peer Reviewed Abstracts Accepted by The Cardiovascular and Interventional Radiological Society of Europe
June 16 2023 - 8:30AM
Microbot Medical Inc. (Nasdaq: MBOT) is encouraged by the continued
participation and level of enthusiasm being demonstrated by the Key
Opinion Leaders (KOL) globally who are using the LIBERTY® Robotic
Surgical System during the Company’s pre-clinical animal studies.
Further displaying their positive experiences and satisfaction, the
Company has been informed that two peer-reviewed abstracts have
been accepted to be presented at the Annual Congress of the
Cardiovascular and Interventional Radiological Society of Europe
(CIRSE). In addition, one of the abstracts was accepted as an oral
presentation.
These peer-reviewed abstracts follow the highly
successful extended joint pre-clinical animal studies held at
leading European-based research labs by a team of seven renowned
European interventional radiologists.
The Company believes that the accumulation of
peer-reviewed data during the pre-clinical animal studies are
invaluable opportunities to gather leading physicians’ and future
users’ insight as it finalizes the necessary steps prior to its
expected First in Human (FIH) and the human clinical trial,
including the Validation & Verification (V&V) and
submission of the Investigation Device Exemption (IDE) phases as
part of its regulatory process.
"Our goal is to increase awareness amongst
leading KOLs to LIBERTY® while we establish the necessary data for
our regulatory process, primarily for the FDA. We believe that the
current and future peer-reviewed data will accelerate adoption of
LIBERTY once commercialized," said Dr. Eyal Morag, Chief Medical
Officer of Microbot Medical. "The physician's desire to take part
in our studies and submit a peer-review abstract, as well as
accepted by one of the biggest interventional radiology societies,
is a testimony of our disruptive solution."
Separately, Dr. Morag recently gave an oral
presentation at the Israeli Conference on Robotics (ICR) annual
meeting. The abstract, which was titled “Use of a
Disposable, Compact, Remote Controlled
“LIBERTY” Robot for Intravascular
Navigation: A New Concept in Endovascular Robotics,”
reviewed the performance of the LIBERTY Robotic Surgical System
during animal feasibility studies. The studies were conducted by
senior, experienced and well-established interventional
radiologists and the system was evaluated on several key metrics,
including performance and safety.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, with the goals of
improving clinical outcomes for patients and increasing
accessibility through the natural and artificial lumens within the
human body.
The LIBERTY® Robotic Surgical System aims to
improve the way surgical robotics are being used in endovascular
procedures today, by eliminating the need for large, cumbersome,
and expensive capital equipment, while reducing radiation exposure
and physician strain. The Company believes the LIBERTY® Robotic
Surgical System’s remote operation has the potential to be the
first system to democratize endovascular interventional
procedures.Further information about Microbot Medical is available
at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions,
risks inherent in the development and/or commercialization of
potential products, including LIBERTY, the outcome of its studies
to evaluate LIBERTY, whether the Company’s core business focus
program and cost reduction plan are sufficient to enable the
Company to continue to focus on its LIBERTY technology while it
seeks additional working capital, any failure or inability to
recruit physicians and clinicians to serve as primary investigators
to conduct regulatory studies which could adversely affect or delay
such studies, uncertainty in the results of pre-clinical and
clinical trials or regulatory pathways and regulatory approvals,
uncertainty resulting from the COVID-19 pandemic, need and ability
to obtain future capital, and maintenance of intellectual property
rights. Additional information on risks facing Microbot Medical can
be found under the heading “Risk Factors” in Microbot Medical’s
periodic reports filed with the Securities and Exchange Commission
(SEC), which are available on the SEC’s web site at www.sec.gov.
Microbot Medical disclaims any intent or obligation to update these
forward-looking statements, except as required by law.
Investor Contact:
Michal Efraty+972-(0)52-3044404IR@microbotmedical.com
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Oct 2023 to Oct 2024